BTIG raised the firm’s price target on Exagen (XGN) to $9 from $5 and keeps a Buy rating on the shares. The company delivered a solid Q1 revenue beat driven by strength in average sales price expansion which exceeded the firm’s expectations, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN: